
June 17 (Reuters) - Verve Therapeutics Inc VERV.O:
LILLY TO ACQUIRE VERVE THERAPEUTICS TO ADVANCE ONE-TIME TREATMENTS FOR PEOPLE WITH HIGH CARDIOVASCULAR RISK
ELI LILLY - PROPOSED DEAL FOR PURCHASE PRICE OF $10.50 PER SHARE IN CASH
ELI LILLY - PROPOSED DEAL FOR A TOTAL POTENTIAL CONSIDERATION OF UP TO $13.50 PER SHARE IN CASH WITHOUT INTEREST
ELI LILLY - TRANSACTION IS NOT SUBJECT TO ANY FINANCING CONDITION
ELI LILLY: CVR HOLDERS WOULD BE ENTITLED TO GET CONTINGENT PAYMENT UPON FIRST PATIENT BEING DOSED WITH VERVE-102 FOR ASCVD IN U.S. PHASE 3 TRIAL